Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Oct 11, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.6K

Annotating CD38 Expression in Multiple Myeloma with [18F]F-Nb1053.

Weijun Wei1, Di Zhang1, Cheng Wang1

  • 1Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.

Molecular Pharmaceutics
|November 30, 2021
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and Evaluation of an Albumin-Binding GPC3-Targeting Peptide for PET Imaging of Hepatocellular Carcinoma.

Molecular pharmaceutics·2026
Same author

CD70-targeted platform for diagnosing and treating multiple myeloma.

Journal for immunotherapy of cancer·2026
Same author

[18F]RCCB6 PET/CT in Diagnosing Clear Cell Renal Cell Carcinomas: A Prospective Comparison Study with [18F]FDG PET/CT and Conventional Imaging.

Cancer discovery·2026
Same author

Trop2-Targeted [<sup>18</sup>F]AlF-RESCA-RT4 ImmunoPET/CT in Guiding Clinical Surgeries of Thyroid Cancers: A Proof-of-Concept Study.

Molecular pharmaceutics·2026
Same author

Immuno-PET Imaging of Tumor Mesothelin Expression with a Gallium-68 Radiolabeled Nanobody.

Molecular pharmaceutics·2026
Same author

Rational Design of Aptamer-Guided Framework Nucleic Acid Delivery Platform for Cancer Radionuclide Theranostics.

ACS nano·2025

A new radioactive tracer, [18F]F-Nb1053, targets CD38 for noninvasive multiple myeloma (MM) diagnosis. This CD38-specific probe shows promise for improving MM management and patient outcomes.

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Biotechnology

Background:

  • Noninvasive diagnosis of multiple myeloma (MM) remains a clinical challenge.
  • CD38 is a key biomarker for MM, making CD38-targeted radiotracers valuable for improved disease management.
  • Developing novel imaging agents is crucial for enhancing diagnostic accuracy in MM.

Purpose of the Study:

  • To develop and evaluate a novel 18F-labeled nanobody ([18F]F-Nb1053) targeting CD38 for noninvasive diagnosis of multiple myeloma (MM).
  • To assess the diagnostic efficacy and specificity of [18F]F-Nb1053 using immuno-PET imaging in preclinical MM models.
  • To explore the potential of [18F]F-Nb1053 as a tool for optimizing MM patient management.

Main Methods:

  • Bioorthogonal click chemistry was employed to label a CD38-specific nanobody (Nb1053-LLQS) with fluorine-18 (18F).
Keywords:
CD38companion diagnosticsimmunoPETmultiple myelomananobody

More Related Videos

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.4K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Related Experiment Videos

Last Updated: Oct 11, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.6K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.4K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
  • The radiochemical purity and immunoreactivity of the developed tracer, [18F]F-Nb1053, were determined.
  • Immuno-positron emission tomography (immunoPET) imaging was performed in disseminated MM.1S-bearing mouse models to evaluate tracer uptake and specificity.

    • Main Results:

    • The [18F]F-Nb1053 tracer was successfully synthesized with high radiochemical purity (>98%) and excellent immunoreactivity.
    • ImmunoPET imaging clearly delineated disseminated MM lesions in preclinical models, with significant uptake observed in bone lesions.
    • Tumor uptake of [18F]F-Nb1053 was reduced following daratumumab premedication, confirming the probe's specificity for CD38.

    Conclusions:

    • A novel CD38-specific radiotracer, [18F]F-Nb1053, has been successfully developed using bioorthogonal click chemistry.
    • The developed tracer demonstrates high specificity and efficacy for detecting multiple myeloma lesions in preclinical models via immunoPET.
    • [18F]F-Nb1053 holds significant potential for clinical translation to improve the noninvasive diagnosis and management of multiple myeloma.